Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Net Income towards Common Stockholders (2021 - 2025)

PAVmed (PAVM) has 5 years of Net Income towards Common Stockholders data on record, last reported at -$6.3 million in Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders changed N/A year-over-year to -$6.3 million; the TTM value through Sep 2025 reached -$811000.0, changed N/A, while the annual FY2024 figure was $32.4 million, 148.88% up from the prior year.
  • Net Income towards Common Stockholders reached -$6.3 million in Q3 2025 per PAVM's latest filing, up from -$10.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $17.7 million in Q1 2025 and bottomed at -$26.2 million in Q3 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$13.4 million, with a median of -$15.3 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 121.7% in 2022, then skyrocketed 177.67% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$17.3 million in 2021, then fell by 18.79% to -$20.5 million in 2022, then grew by 22.54% to -$15.9 million in 2023, then skyrocketed by 89.92% to -$1.6 million in 2024, then tumbled by 294.51% to -$6.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$6.3 million in Q3 2025, -$10.6 million in Q2 2025, and $17.7 million in Q1 2025.